Evidence map›Paper›PMID 41301699›Full record

ReviewBiomedicines2025

Tertiary Hyperparathyroidism in Diabetic Nephropathy: An Underrecognized Complication-A Narrative Review.

Mirona Costea, Dana-Mihaela Tilici, Diana Loreta Paun, Vanda Roxana Nimigean, Sorin Constantin Paun, Rucsandra Elena Danciulescu-Miulescu

Abstract readReview
In one paragraph

Review in Biomedicines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mirona CosteaDoctoral School, University of Medicine and Pharmacy "Carol Davila", 020021 Bucharest, Romania.
Dana-Mihaela TiliciDoctoral School, University of Medicine and Pharmacy "Carol Davila", 020021 Bucharest, Romania.ORCID 0009-0001-5655-2694
Diana Loreta PaunEndocrinology Department, Bucharest University Emergency Hospital, 050098 Bucharest, Romania.
Vanda Roxana NimigeanFaculty of Medicine, University of Medicine and Pharmacy "Carol Davila", 020021 Bucharest, Romania.
Sorin Constantin PaunFaculty of Medicine, University of Medicine and Pharmacy "Carol Davila", 020021 Bucharest, Romania.ORCID 0009-0007-8301-4131
Rucsandra Elena Danciulescu-MiulescuFaculty of Medicine, University of Medicine and Pharmacy "Carol Davila", 020021 Bucharest, Romania.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tertiary hyperparathyroidism (THPT) arises in patients with chronic kidney disease (CKD) as a consequence of prolonged secondary hyperparathyroidism and is marked by autonomous parathyroid hormone (PTH) secretion. In some cases, parathyroid hyperplasia persists even after successful renal transplantation, resulting in sustained PTH elevation and hypercalcaemia. These alterations contribute to bone loss, vascular calcification, and increased cardiovascular risk. Management includes medical therapy with calcimimetics or vitamin D analogues and surgical intervention via parathyroidectomy. However, optimal timing and treatment strategy remain uncertain. This review examines the pathophysiology, clinical manifestations, and current management paradigms of THPT, with an emphasis on areas that require further research and consensus.

Indexed as

chronic kidney disease (CKD)diabetic nephropathyparathyroid hormone (PTH)tertiary hyperparathyroidism (THPT)

Identifiers

PMID41301699
PMCPMC12650327

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.